GEN Exclusives

More »

GEN News Highlights

Back to Item »

Memory Pharmaceuticals and Roche to Add Biomarker Trials to Schizophrenia Development Program

P50 sensory gating and mismatch negativity will be evaluated as potential efficacy markers for nicotinic alpha-7 agonists in this disorder.

Forward this item to a colleague:


 
   

(Separate multiple addresses by commas)

   

(Separate multiple addresses by commas)

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

New Drugs for Ebola

Do you think that biopharma companies should not have to go through the normal drug approval process in order to get potential life-saving therapies to Ebola patients more quickly?